Discover the Therapeutic Benefits of ACTIMMUNE® (Interferon gamma-1b)
ACTIMMUNE® (Interferon gamma-1b) is indicated:
- For reducing the frequency and severity of serious infections associated with Chronic Granulomatous Disease (CGD)
- For delaying time to disease progression in patients with severe, malignant osteopetrosis (SMO)
What is Chronic Granulomatous Disease (CGD)?
CGD is a primary immunodeficiency disorder of phagocytes that results from impaired killing of fungi and catalase-positive bacteria, which can lead to severe and recurrent infections. CGD can also be characterized by dysregulated inflammatory response resulting in granuloma formation and other inflammatory disorders.2,3
What is Severe, Malignant Osteopetrosis (SMO)?
Severe, malignant osteopetrosis (SMO) is a genetic disease of the bones and is sometimes referred to as marble bone disease or malignant infantile osteopetrosis (MIOP) because it occurs in very young children. Severe, malignant osteopetrosis is a severe form of malignant osteopetrosis.4,5
Hear personal stories of patients and caregivers,
learn about administering ACTIMMUNE®
and the proposed mechanism of action (MOA).
References: 1. ACTIMMUNE® (Interferon gamma-1b) Full Prescribing Information. Roswell, GA: Horizon Pharma, Inc; 2015. 2. Leiding JW, Holland SM. Chronic granulomatous disease. In: Pagon RA, Bird TD, Dolan CR, et al, eds. GeneReviews. Seattle, WA: University of Washington; 2012. 3. Song E, Jaishankar GB, Saleh H, et al. Chronic granulomatous disease: a review of the infectious and inflammatory complications. Clin Mol Allergy. 2011;9(1):10. doi:10.1186/1476-7961-9-10. 4. Stark Z, Savarirayan R. Osteopetrosis. Orphanet J Rare Dis. 2009;4:5. 5. Wilson CJ, Vellodi A. Autosomal recessive osteopetrosis: diagnosis, management, and outcome. Arch Dis Child. 2000;83(5):449-452.